For research use only. Not for therapeutic Use.
EBI-907（Cat No.:I006580）is a selective and potent inhibitor of the enzyme dipeptidyl peptidase I (DPP-I), which plays a crucial role in the activation of various proteases involved in immune responses. By inhibiting DPP-I, EBI-907 prevents the activation of cathepsins, which are involved in the processing of certain pro-inflammatory cytokines and immune cell activation. This inhibition can modulate immune responses, making EBI-907 a potential therapeutic candidate for autoimmune diseases, inflammation, and certain cancers. Preclinical studies are ongoing to assess its efficacy and safety in clinical settings.
| Catalog Number | I006580 |
| CAS Number | 1581764-31-9 |
| Synonyms | EBI-907; EBI 907; EBI907; CAS# 1581764-31-9;N-(2-chloro-3-(1-cyclopropyl-8-methoxy-3H-pyrazolo[3,4-c]isoquinolin-7-yl)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide |
| Molecular Formula | C23H21ClF2N4O3S |
| Purity | ≥95% |
| Target | B-RafV600E inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | N-[2-chloro-3-(1-cyclopropyl-8-methoxy-2H-pyrazolo[3,4-c]isoquinolin-7-yl)-4-fluorophenyl]-3-fluoropropane-1-sulfonamide |
| InChI | InChI=1S/C23H21ClF2N4O3S/c1-33-18-10-14-13(11-27-23-20(14)22(28-29-23)12-3-4-12)9-15(18)19-16(26)5-6-17(21(19)24)30-34(31,32)8-2-7-25/h5-6,9-12,30H,2-4,7-8H2,1H3,(H,27,28,29) |
| InChIKey | JSKJFDXTKYWPAH-UHFFFAOYSA-N |
| SMILES | COC1=C(C=C2C=NC3=NNC(=C3C2=C1)C4CC4)C5=C(C=CC(=C5Cl)NS(=O)(=O)CCCF)F |
| Reference | </br>1:EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Zhang J, Lu B, Liu D, Shen R, Yan Y, Yang L, Zhang M, Zhang L, Cao G, Cao H, Fu B, Gong A, Sun Q, Wan H, Zhang L, Tao W, Cao J.Cancer Biol Ther. 2016;17(2):199-207. doi: 10.1080/15384047.2016.1139231. Epub 2016 Jan 25. PMID: 26810733 Free PMC Article</br>2:Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers. Lu B, Cao H, Cao J, Huang S, Hu Q, Liu D, Shen R, Shen X, Tao W, Wan H, Wang D, Yan Y, Yang L, Zhang J, Zhang L, Zhang L, Zhang M.Bioorg Med Chem Lett. 2016 Feb 1;26(3):819-23. doi: 10.1016/j.bmcl.2015.12.086. Epub 2015 Dec 24. PMID: 26739779 |
